Key result
A 52-year-old male with primary cardiac B-cell lymphoblastic lymphoma experienced disease recurrence and died from cardiac failure 75 days after autologous bone marrow transplantation.
Case Report (n=1)
Primary cardiac B-cell lymphoblastic lymphoma is a rare disease with a grim prognosis, and the authors suggest considering intensive therapies like auto-BMT as a first treatment option.
Poor survival after auto-BMT in cardiac lymphoma warrants caution with intensive upfront therapy; leaves open optimal initial management for this rare entity.
Primary cardiac lymphoma (PCL) is a rare neoplasm, the majority of cases of which are non-Hodgkin's, diffuse large B-cell (DLBCL). We report the first case of an adult with PCL B-cell lymphoblastic lymphoma whose disease evolution was grim. A 52-year-old male reported dyspnea and facial swelling lasting for 4 months and upon a physical examination he presented bradycardia, jugular venous engorgement, and hypophonesis of cardiac sounds. An electrocardiography (Echo) revealed a right atrial mass and nodules at the pericardium. The patient was treated with R-Hyper-CVAD (rituximab plus cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and presented very short remission. At this time, we used R-ICE (rituximab plus ifosfamide, carboplatin, and etoposide) chemotherapy and the patient underwent complete remission after two courses and received autologous bone marrow transplantation (auto-BMT). After 75 days of follow-up, the patient reported dyspnea and a new Echo showed a recurrence of the disease. The patient died due to cardiac failure. PCL is a rare disease with an unfavorable prognosis and a prompt diagnosis and treatment are fundamental to survival. We believe that more intensive therapies, such as auto-BMT, should be considered as a first treatment option.
No takes yet. Share an insight, caveat, or question.
A 2015 study conducted a case report in Primary cardiac lymphoblastic B-cell lymphoma (n=1). R-Hyper-CVAD followed by R-ICE and autologous bone marrow transplantation was evaluated on Disease remission and survival. A 52-year-old male with primary cardiac B-cell lymphoblastic lymphoma experienced disease recurrence and died from cardiac failure 75 days after autologous bone marrow transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: